Evaluate effectiveness of Carvedilol CR on Micro T-Wave Alternans in high risk hypertensives
The effect of Carvedilol CR on Micro T-Wave Alternans will be assessed in 30 hypertensives with stage 4 or 5 chronic kidney disease utilizing a cross-over design and contrasting no treatment against active treatment periods of 8 weeks.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Enrollment
6
All enrolled participants were randomized to receive Carvedilol or Placebo in a 2-way crossover design. Each intervention was administered over 8 weeks before switching to the alternative intervention. The study was terminated early, and data were not unblinded so participants cannot be reported separately.
University of Toledo, Health Science Campus
Toledo, Ohio, United States
Site Rhode Island Hospital
Providence, Rhode Island, United States
Micro T- Wave Alternans
Time frame: week 1, 8, 11, 18
Oxidized LDL
Time frame: week 1, 8, 11, 18
Interleukin-6
Time frame: week 1, 8, 11, 18
Plasma C-reactive Protein
Time frame: week 1, 8, 11, 18
Plasma Cardiac Troponin T
Time frame: week 1, 8, 11, 18
Plasma NT-pro BNP
Time frame: week 1, 8, 11, 18
Plasma F2-isoprostanes
Time frame: week 1, 8, 11, 18
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.